International Assets Investment Management LLC bought a new stake in shares of MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 25,000 shares of the company’s stock, valued at approximately $29,000.
Separately, Suncoast Equity Management increased its holdings in shares of MIRA Pharmaceuticals by 125.0% during the third quarter. Suncoast Equity Management now owns 90,000 shares of the company’s stock valued at $117,000 after purchasing an additional 50,000 shares during the period. 35.16% of the stock is owned by hedge funds and other institutional investors.
MIRA Pharmaceuticals Stock Performance
Shares of NASDAQ MIRA opened at $1.17 on Wednesday. MIRA Pharmaceuticals, Inc. has a 1 year low of $0.51 and a 1 year high of $5.01. The firm has a market cap of $19.38 million, a P/E ratio of -2.09 and a beta of 2.12. The stock has a fifty day moving average price of $1.28 and a two-hundred day moving average price of $1.43.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on MIRA shares. Rodman & Renshaw began coverage on shares of MIRA Pharmaceuticals in a report on Monday, September 30th. They issued a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW raised shares of MIRA Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 30th.
Check Out Our Latest Report on MIRA Pharmaceuticals
Insider Buying and Selling at MIRA Pharmaceuticals
In other MIRA Pharmaceuticals news, CEO Erez Aminov sold 55,410 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $1.39, for a total value of $77,019.90. Following the transaction, the chief executive officer now owns 1,105,790 shares of the company’s stock, valued at approximately $1,537,048.10. This represents a 4.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.65% of the stock is owned by corporate insiders.
MIRA Pharmaceuticals Company Profile
MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than MIRA Pharmaceuticals
- Overbought Stocks Explained: Should You Trade Them?
- The Fed Is More Likely to Hike Than Cut Rates in 2025
- What Does Downgrade Mean in Investing?
- Investors Navigate Uncertainty by Seeking Refuge in Gold and Oil
- How to Use the MarketBeat Dividend Calculator
- Archer Aviation Shares Slide, Now Bargain Priced for 2025
Want to see what other hedge funds are holding MIRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA – Free Report).
Receive News & Ratings for MIRA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MIRA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.